Sponsors (3)
Treats drugs as misbranded if their approval or license holder ran direct-to-consumer ads in the prior 30 days, defined to include TV, radio, print, digital, and social media.
The bill reduces potentially misleading drug advertising and nudges clinicians toward evidence-based prescribing — improving patient safety and lowering some promotion-driven costs — but increases compliance and legal burdens that could raise drug prices, limit patient access to manufacturer information, and create market and regulatory uncertainty.
Patients with chronic conditions will be exposed to fewer potentially misleading consumer-targeted promotions for recently marketed prescription drugs, reducing exposure to incomplete or promotional-only claims.
Clinicians, hospitals, and other healthcare workers will have clearer incentives to rely on peer-reviewed and clinical information rather than direct-to-consumer marketing, which can improve prescribing decisions and clinical care.
Payers and taxpayers (including Medicare beneficiaries) could see reduced spending if marketing-driven demand for newly advertised drugs falls, lowering utilization prompted primarily by promotion.
Patients with chronic conditions may face higher drug costs or reduced promotional access because drug manufacturers will incur greater compliance costs and legal risk from stricter advertising rules, which manufacturers could pass on as higher prices.
Patients with chronic conditions may receive less information about new treatment options through mainstream advertising channels if companies scale back direct-to-consumer advertising, making it harder for some people to learn about available therapies.
Hospitals, health systems, manufacturers, and clinicians could face regulatory uncertainty from a broad statutory definition and a 30-day lookback window, leading to enforcement disputes and potential delays in access to information while legal interpretations play out.
Based on analysis of 2 sections of legislative text.
Official title: To ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.
Introduced July 22, 2025 by Jerrold Lewis Nadler · Last progress July 22, 2025
Makes certain prescription drugs subject to misbranding rules if their manufacturer, licensee, or application holder has run direct-to-consumer (DTC) advertising in the prior 30 days. It adds a definition of DTC advertising (TV, radio, print, digital, social media) and applies the rule to FDA-approved drugs and licensed biologics, effective 30 days after enactment. The change narrows a current statutory exception by creating a new disqualifying condition: drugs with recent consumer-targeted promotional communications can be treated as misbranded under the Federal Food, Drug, and Cosmetic Act, which would restrict or eliminate routine DTC marketing practices for prescription drugs and biologics.